B. Riley Securities’ 2024 Virtual Oncology Conference
Date: Wednesday, January 18, 2024 Link: Click here
B. Riley Securities’ 2024 Virtual Oncology Conference Read More »
Date: Wednesday, January 18, 2024 Link: Click here
B. Riley Securities’ 2024 Virtual Oncology Conference Read More »
November 13, 2023 08:00 ET – VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on track to complete enrollment in the first half of 2024; multiple patients have received second doses of VCN-01, which continues to be well tolerated with a safety profile consistent with
November 13, 2023 08:00 ET – VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia para el adenocarcinoma ductal de páncreas metastásico, sigue el curso previsto para completar la inscripción en el primer semestre de 2024; muchos pacientes han recibido la segunda dosis de VCN-01, que sigue siendo bien tolerado y mantiene
October 23, 2023 07:00 ET -Results show enhanced patient survival, correlating with VCN-01 mediated increases in the CPS score, a key determinant of outcomes with anti-PD-(L)1 checkpoint inhibitor therapies- -Key Opinion Leader (KOL) webinar featuring expert oncologist Ricard Mesia M.D., Ph.D., to be held today, Monday, October 23, 2023 at 8:00 a.m. ET- ROCKVILLE, Md.,
October 16, 2023 08:00 ET -Results from investigator-sponsored study in collaboration with the Institut Catala d’Oncologia (ICO) show enhanced patient survival, correlating with VCN-01 induced upregulation of PD(L)-1- -Key Opinion Leader (KOL) webinar featuring expert oncologist Ricard Mesia M.D., Ph.D., to be held Monday, October 23, 2023 at 8:00 a.m. ET- ROCKVILLE, Md., Oct. 16,
– Initiated dosing at U.S. sites for VIRAGE – – Second doses of intravenous VCN-01 administered to patients in Spain and were well tolerated – – VIRAGE remains on track to complete enrollment in the first quarter of 2024 – ROCKVILLE, Md., Aug. 02, 2023 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a
May 23, 2023 08:00 ET -Appointment expected to aid advancement of Theriva’s discovery program and strengthen collaboration with the Institut Catala d’Oncologia (ICO) and the Biomedical Research Institute of Bellvitge (IDIBELL)- ROCKVILLE, Md., May 23, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to
May 23, 2023 15:40 ET -Con este nombramiento se espera contribuir al avance del programa de descubrimiento de Theriva y al fortalecimiento de la colaboración con el Institut Català d’Oncologia (ICO) y el Institut d’Investigació Biomèdica de Bellvitge (IDIBELL)- ROCKVILLE, Maryland, May 23, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), («Theriva» o la
May 11, 2023 22:48 ET – Prosigue la inscripción de pacientes en VIRAGE, el ensayo clínico de fase 2b de VCN-01 administrado sistémicamente en combinación con quimioterapia en el adenocarcinoma ductal pancreático – – Presentación de datos del ensayo clínico de fase 1b/2a en curso de SYN-004 (ribaxamasa) en receptores de trasplantes alogénicos de células
May 11, 2023 08:00 ET – Continued to enroll patients in VIRAGE, the Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma – – Presented data from the ongoing Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant recipients at the 33rd European Congress of